NMN vs NR: Comparing NAD+ Precursors — Evidence & Differences

Both effectively raise blood NAD+ levels in human trials. NR has more published human data (Martens 2018: ~60% elevation at 1,000 mg/day). NMN also elevates NAD+ with good tolerability in newer, smaller trials. Neither is proven superior in a head-to-head trial.

Both are absorbed and convert to NAD+. NR is phosphorylated to NMN inside cells via NRK1/2. NMN may use the Slc12a8 transporter for direct uptake in some tissues, though this is debated. Direct head-to-head bioavailability data is limited.

NMN is one step closer to NAD+ in the salvage pathway. NR is converted to NMN inside cells by NRK1/2 enzymes before becoming NAD+. NR has GRAS status and more human trials; NMN's regulatory status varies by market.

NR has more published human clinical trials, including the Martens 2018 RCT showing cardiovascular benefits. NMN trials are newer and smaller but growing rapidly (30+ registered on ClinicalTrials.gov as of 2024).

Both have excellent safety records in published human trials — no serious adverse events for NMN (up to 1,200 mg/day) or NR (up to 2,000 mg/day). NR has GRAS status, giving it a stronger regulatory safety profile.

Common doses: NMN 250–1,000 mg/day; NR 300–1,000 mg/day. Both show NAD+ elevation in this range. Higher doses are used in some trials. Follow product labels and consult a healthcare provider.

The Slc12a8 NMN transporter was identified in murine intestinal cells (Grozio 2019), suggesting direct uptake. The finding remains debated and its significance in humans is uncertain.

Combining them has not been studied. Both converge on the NAD+ salvage pathway, so combining may not provide additional benefit beyond a sufficient dose of either. Consult your healthcare provider.

Prices fluctuate, but NR (with GRAS status and wider availability) is often competitively priced. NMN's regulatory uncertainty has affected supply and pricing. Costs are generally comparable at typical doses.

Both are being studied for age-related NAD+ decline (which drops ~50% by age 60). Human outcome data (beyond NAD+ elevation) is still emerging for both. Neither is proven to reverse aging in humans.

NAD+ declines approximately 50% between ages 40 and 60, driven by increased CD38 expression and PARP consumption. This decline is linked to reduced mitochondrial function and sirtuin activity.

No serious adverse events have been reported in trials up to 1,200 mg/day (NMN) or 2,000 mg/day (NR). Excessively high NAD+ could theoretically affect NAD+-consuming enzymes, but this hasn't been demonstrated clinically.

Both require proper storage (cool, dry). NR is generally considered more shelf-stable. NMN can degrade if exposed to moisture and heat — follow storage instructions.

Some evidence suggests NMN may be taken up directly by certain tissues (via Slc12a8), while NR converts to NMN intracellularly. Detailed tissue distribution comparisons in humans are limited.

Researchers vary — some take NR (more human data, GRAS status), others take NMN. Personal anecdotes are not evidence; the choice should be based on evidence and individual goals, discussed with a healthcare provider.